Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Merola, Elettra; Grana, Chiara Maria

doi:10.3390/cancers15112975

Cited by 15 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NETTER 1 study demonstrated the significant benefits of PRRT in GEP-NETs and introduced the potential for therapeutic effects in neuroendocrine tumors [ 2 ]. The ability to target lesions due to somatostatin receptor expression offers the potential for targeted treatment of multiple foci, whereas the effect of treatment on adjacent clones within the lesion via the cross-fire effect may help treat heterogeneous metastatic foci [ 51 ]. However, it should be noted that this study did not include LNETs and its efficacy in these tumors has not been confirmed.…”

Section: Navigating Therapeutic Strategies: Efficacy In Treating Lung...mentioning

confidence: 99%

Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?

Evangelou,

Vamvakaris,

Papafili

et al. 2024

Cancers

View full text Add to dashboard Cite

Lung neuroendocrine tumors (LNETs) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are two distinct types of neuroendocrine tumors (NETs) that have traditionally been treated as a single entity despite originating from different sources. Although they share certain phenotypic characteristics and the expression of neuroendocrine markers, they exhibit differences in their microenvironment, molecular mutations, and responses to various therapeutic regimens. Recent research has explored the genetic alterations in these tumors, revealing dissimilarities in the frequently mutated genes, the role of EGFR in carcinogenesis, the presence of transcription factors, and the immunogenicity of the tumor and its microenvironment. Spread Through Air Spaces (STAS), a phenomenon unique to lung carcinomas, appears to play a crucial role in LNET prognosis. These distinctions are also evident in the cascade response of lung and GI tract neuroendocrine tumors to somatostatin analogs, Peptide Receptor Radionuclide Therapy (PRRT), chemotherapy, and immunotherapy. Identifying similarities and differences between the two groups may improve our understanding of the underlying mechanisms and facilitate the development of more effective treatment strategies.

show abstract

Section: Navigating Therapeutic Strategies: Efficacy In Treating Lung...mentioning

confidence: 99%

Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?

Evangelou,

Vamvakaris,

Papafili

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…THPs are also used for peptide receptor radionuclide therapy (PRRT), which combines a tumor-homing peptide with a radionuclide or radioactive isotope as the therapeutic substance [ 167 ]. Cholecystokinin (CCK) receptors bind to gastrin, a 33 amino acid peptide hormone, and CCK2 receptor is abundant in tumors [ 168 ].…”

Section: Peptide-based Approaches For Cancer Treatmentmentioning

confidence: 99%

“…Recent advancements in biopharmaceutical engineering have resulted in the development of various drugs based on peptides or proteins [ 7 , 167 , 194 , 208 , 209 ]. The route of drug administration significantly affects its effectiveness as a treatment [ 210 , 211 ].…”

Section: Peptides In Applicationsmentioning

confidence: 99%

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

Nhàn,

Yamada,

Yamada

2023

IJMS

View full text Add to dashboard Cite

Peptide-based strategies have received an enormous amount of attention because of their specificity and applicability. Their specificity and tumor-targeting ability are applied to diagnosis and treatment for cancer patients. In this review, we will summarize recent advancements and future perspectives on peptide-based strategies for cancer treatment. The literature search was conducted to identify relevant articles for peptide-based strategies for cancer treatment. It was performed using PubMed for articles in English until June 2023. Information on clinical trials was also obtained from ClinicalTrial.gov. Given that peptide-based strategies have several advantages such as targeted delivery to the diseased area, personalized designs, relatively small sizes, and simple production process, bioactive peptides having anti-cancer activities (anti-cancer peptides or ACPs) have been tested in pre-clinical settings and clinical trials. The capability of peptides for tumor targeting is essentially useful for peptide–drug conjugates (PDCs), diagnosis, and image-guided surgery. Immunomodulation with peptide vaccines has been extensively tested in clinical trials. Despite such advantages, FDA-approved peptide agents for solid cancer are still limited. This review will provide a detailed overview of current approaches, design strategies, routes of administration, and new technological advancements. We will highlight the success and limitations of peptide-based therapies for cancer treatment.

show abstract

“…Peptide receptor radionuclide therapy (PRRT) selectively attacks tumor cells by binding to peptides expressed on their surface [ 8 ]. NETs frequently express membrane-localized somatostatin receptors (SSTRs), making these receptors suitable targets for PRRT using somatostatin analogs (SSAs).…”

Section: Introductionmentioning

confidence: 99%

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report

Umino,

Nara,

Kobayashi

et al. 2024

surg case rep

View full text Add to dashboard Cite

Background Peptide receptor radionuclide therapy (PRRT) serves as a novel and effective treatment option for somatostatin receptor-positive unresectable liver metastases of pancreatic neuroendocrine tumors (PNETs). However, there are few reported cases of surgical resection for initially unresectable liver metastases of PNET that were converted to resectable after PRRT. Here we report a case where PRRT and somatostatin analogs (SSAs) led to a pathological complete response of initially unresectable multiple liver metastases following PNET resection. Case presentation A 52-year-old man underwent pylorus-preserving pancreaticoduodenectomy for PNET at age 40 and subsequent hepatectomies for resectable liver metastases at 44 and 47 years of age. At age 48, a follow-up examination revealed unresectable multiple liver metastases, and PRRT with 177Lu-DOTATATE therapy was initiated. After four cycles of PRRT, most liver metastases diminished according to imaging studies, and the remaining two hepatic lesions continued to shrink with additional lanreotide. Conversion surgery for liver metastases was successfully performed, revealing no viable tumor cells in tissue specimens. Seventeen months after surgery, imaging showed no detectable residual tumor or recurrence. We present a review of the relevant literature that highlights the significance of our findings. Conclusions This rare case highlights the pathological complete response of initially unresectable multiple liver metastases achieved by PRRT and SSAs following PNET resection, suggesting their potential as a multimodality treatment option for unresectable PNET.

show abstract

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Cited by 15 publications

References 51 publications

Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?

Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?

Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions

Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report

Contact Info

Product

Resources

About